Nasdaq

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with ...
Nasdaq

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License ...
Nature

Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein.

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
ALZFORUM

ApoE Binds Complement Protein, Keeps Inflammatory Cascade in Check

This story was updated on February 5, 2019. Just when you thought ApoE biology couldn’t get any more complicated, scientists have discovered a new function for this apolipoprotein. According to a ...
ALZFORUM

Neuronal SRPX2 Spoils Microglial Appetite for Synapses

For better or worse, complement proteins tag synapses for elimination by microglia. A paper published July 13 in Nature Neuroscience identifies a neuronal protein that keeps this process in check.
Pharmabiz

Complement Therapeutics receives US FDA clearance to begin Opti-GAIN phase I/II trial of CTx001 in patients with GA secondary to AMD

Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, announced that the US Food and Drug Administration (FDA) has ...